New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
07:12 EDTTEVATeva reports Q4 Generic medicines sales $2.7B, Specialty medicines sales $2.1B
Global revenues recorded by Teva for Copaxone increased 14%, or 15% in local currency terms, to $1.1B compared to $927M in the fourth quarter of 2011. The increase primarily resulted from the take-back of marketing and distribution rights in Europe and continued market share leadership. Reports Q4 Treandra revenue $161M. Azilect revenues recorded by Teva increased 4% to $86M, while global in-market revenues increased 4% to $113M, primarily due to increased demand in the U.S. and Europe and a price increase.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use